• Investment World
• eWorld
• Catalyst
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• The Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

New Delhi , Nov. 28

THE appetite of domestic pharma companies for acquiring entities abroad has not diminished. Both Nicholas Piramal India Ltd (NPIL) and Jubilant Organosys today said that they were looking for overseas buys.

"We are looking at acquisition in the UK and North America. We are interested in process development and manufacturing new molecules through the acquisitions, and not just in generics," said Mr Ajay Piramal, Chairman, NPIL. "We are looking for acquisition to provide drugs in the global market and not just looking at the market in those particular countries," he added.

Jubilant Organosys on Monday said it was looking at acquiring a manufacturing unit in China even as it continues to scout for acquisitions in the domestic and international market. "We are looking to have a presence in China by acquiring a manufacturing unit to produce fine chemicals," said Mr Bhartia. While the size of the acquisition is not a major issue, the fit is important.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

More Stories on : Pharmaceuticals

Stories in this Section
Jitters for Tamil Nadu as another storm brews

Copyright © 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line